Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434321 | 0.90 | RORC (0.57) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434508 | 0.86 | RORC (0.69) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434271 | 0.85 | RORC (0.54) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434493 | 0.85 | RORC (0.68) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434030 | 0.85 | RORC (0.71) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434241 | 0.84 | RORC (0.67) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL16092755 | 0.83 | RORC (0.66) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434593 | 0.83 | RORC (0.64) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL16092733 | 0.82 | RORC (0.67) | RORCKDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL17434545 | 0.81 | RORC (0.62) | RORCKDM4ESMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | RORC 2/4885KDM4E 728/4885SMN1; SMN2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.